Jenny Green, 71 from Hertfordshire, was diagnosed in 2017 and was part of the clinical trials that proved the drug worked.
She said: “I seem to have tolerated it very well, with hardly any side effects at all. That’s been amazing!
“I had a scan that showed my cancer nodules were shrinking, and my bloods were coming back into range – which is all pretty good to hear.”
The drug has been approved by the medicines watchdog, the National Institute for Health and Care Excellence (NICE), in ovarian, peritoneal and fallopian tube cancer if chemotherapy no longer works and the cancers have the right markings.
NHS England says it will pay for the drug. Wales and Northern Ireland normally follow the same rules, while Scotland makes its own decisions.
Dr Rowan Miller, who ran the clinical trials at UCLH, said she was “really excited” this drug was coming to the NHS after a 20-year search for better medications.
“Finally, there’s a drug that’s available, that improves survival for this group of patients and in addition, the patients get on with the treatment well and find it easier to manage than standard chemotherapy,” she told me.
